CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer

Dirk De Ruysscher, Suresh Ramalingam, James Urbanic, David E. Gerber, Daniel S.W. Tan, Junliang Cai, Ang Li, Solange Peters

Hematology & Oncology
SPH-Public Health
Internal Medicine
Peter O'Donnell Jr. School of Public Health

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer

Fingerprint

Medicine & Life Sciences